Does testing for more CFTR mutations yield greater coverage? Do your panels reflect your testing population’s diversity? Many CFTR panels were principally designed to detect mutations that are common in Caucasians. Recent studies, however, have shown that many CFTR carriers may be missed in ethnically-diverse populations, including the US demographic. This workshop will evaluate the quality versus quantity of variants in CFTR mutation testing, relate this concept to the design, performance, and simplicity of the AmplideX® PCR/CE CFTR Kit*, and translate the benefits of this kit to the streamlined, scalable, and rapid detection of mutations across different populations.
In response to the worldwide outbreak of COVID-19, Asuragen developed a number of Armored RNA controls to safely test for the presence of the novel coronavirus as an alternative to working with live virus. Although Armored controls have been used in IVD assays for more than 20 years, the technology this year has quickly been adopted worldwide to allow companies to rapidly pivot focus. Here we highlight case studies where Armored Controls are being used to not only assist in pandemic research efforts, but push the limits of quantitative diagnostic testing.
Evan Brakefield, Account Manager, Asuragen
* Product in development. Specifications not finalized.